6.27
+0.415(+7.09%)
Currency In USD
| Previous Close | 5.85 |
| Open | 5.89 |
| Day High | 6.51 |
| Day Low | 5.89 |
| 52-Week High | 6.51 |
| 52-Week Low | 3.38 |
| Volume | 3.18M |
| Average Volume | 3.86M |
| Market Cap | 1.92B |
| PE | 62.65 |
| EPS | 0.1 |
| Moving Average 50 Days | 5.56 |
| Moving Average 200 Days | 4.8 |
| Change | 0.42 |
If you invested $1000 in MannKind Corporation (MNKD) 10 years ago, it would be worth $1,899.06 as of January 08, 2026 at a share price of $6.265. Whereas If you bought $1000 worth of MannKind Corporation (MNKD) shares 5 years ago, it would be worth $1,842.65 as of January 08, 2026 at a share price of $6.265.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MannKind Provides Business Updates and 2026 Growth Drivers
GlobeNewswire Inc.
3 hours ago
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiom
MannKind Shares FUROSCIX® Business Updates
GlobeNewswire Inc.
Dec 23, 2025 1:05 PM GMT
FDA approves FUROSCIX® for use in pediatric patients weighing 43kg or aboveUSPTO issues five patents for FUROSCIX ReadyFlow™ Autoinjector WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
GlobeNewswire Inc.
Dec 01, 2025 1:05 PM GMT
If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 secondsWould potentially provide a cost-effective and convenient option to address episodes of fluid buildup at